Abstract
In the last two decades a tremendous development has been noticed in our understanding of the purinergic system, consisting of heterogeneously expressed purinoceptor subtypes and its classical agonists: e.g., adenosine triphosphate, uridine triphosphate or complex dinucleoside polyphosphates. These agonists exert multiple effects on the vascular system: they regulate the relaxation and constriction of arterial blood vessels, lead to proliferation and migration in endothelial cells and vascular smooth muscle cells, and mediate potent proinflammatory responses or phenotypic cell changes. This review focuses on the P2 purinoceptor subtype P2Y and its pleiotropic effects in the vascular wall under physiological and pathophysiological condition. Various experimental and clinical studies provide evidence that pharmacological targeting of P2Y might be effective in reducing vascular alterations under disease conditions.
Keywords: Dinucleoside polyphoshates, nucleotides, purinoceptors, P2Y, vascular disease, purinergic system, agonists, proliferation, migration, endothelial cells.
Current Pharmaceutical Design
Title:P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease
Volume: 18 Issue: 37
Author(s): Mirjam Schuchardt, Markus Tolle and Markus van der Giet
Affiliation:
Keywords: Dinucleoside polyphoshates, nucleotides, purinoceptors, P2Y, vascular disease, purinergic system, agonists, proliferation, migration, endothelial cells.
Abstract: In the last two decades a tremendous development has been noticed in our understanding of the purinergic system, consisting of heterogeneously expressed purinoceptor subtypes and its classical agonists: e.g., adenosine triphosphate, uridine triphosphate or complex dinucleoside polyphosphates. These agonists exert multiple effects on the vascular system: they regulate the relaxation and constriction of arterial blood vessels, lead to proliferation and migration in endothelial cells and vascular smooth muscle cells, and mediate potent proinflammatory responses or phenotypic cell changes. This review focuses on the P2 purinoceptor subtype P2Y and its pleiotropic effects in the vascular wall under physiological and pathophysiological condition. Various experimental and clinical studies provide evidence that pharmacological targeting of P2Y might be effective in reducing vascular alterations under disease conditions.
Export Options
About this article
Cite this article as:
Schuchardt Mirjam, Tolle Markus and van der Giet Markus, P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582504
DOI https://dx.doi.org/10.2174/138161212803582504 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Effects of Thiazolidinediones on Coronary Artery Disease: Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Hepatobiliary Diseases and Insulin Resistance
Current Medicinal Chemistry Antidiabetic Oils
Current Diabetes Reviews Subject Index To Volume 6
Current Molecular Medicine NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Left Atrial Appendage Closure -The WATCHMAN Device
Current Cardiology Reviews Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy Ethical and Social Issues in Pharmacogenomics Testing
Current Pharmaceutical Design Biophysical Modeling and Associated Signal Modeling in Functional Magnetic Resonance Imaging
Neuroscience and Biomedical Engineering (Discontinued) Pneumonia Caused by Staphylococcus aureus
Current Respiratory Medicine Reviews Free Radicals in Living Systems: In Vivo Detection of Bioradicals with EPR Spectroscopy
Current Organic Chemistry Subject Index To Volume 4
Current Vascular Pharmacology Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Can We Move Forward After ADVANCE?
Vascular Disease Prevention (Discontinued) Tyrosine Kinase Inhibitors
Current Cancer Drug Targets